Showing results (101-110 of 181) with videos related to

Sort By:
Pageof 19
Antimicrobial Agents and Chemotherapy|June 20, 2007
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice dailyEdward P Acosta, Michelle A Kendall, John G Gerber, et al.
The Journal of Infectious Diseases|April 21, 2010
African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapyJeffrey A Canter, Gregory K Robbins, Doug Selph, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 6, 2003
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group studyDavid W Haas, Hulin Wu, Haihong Li, et al.
Pharmacogenetics and Genomics|August 21, 2020
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapineDavid W Haas, Anthony T Podany, Yajing Bao, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2024
Estimating optimal therapeutic drug levels of anti-tuberculosis medications based on treatment safety and effectivenessGustavo Amorim, David W Haas, Marcelo Cordeiro-Santos, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 17, 2006
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicityMarylyn D Ritchie, David W Haas, Alison A Motsinger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2011
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267Kelly E Dooley, Jeong-Gun Park, Susan Swindells, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|December 2, 2010
Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participantsBenjamin J Grady, Eric S Torstenson, Paul J McLaren, et al.
The Journal of Infectious Diseases|May 5, 2022
Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency VirusZinhle Cindi, Aida N Kawuma, Gary Maartens, et al.
Open Forum Infectious Diseases|April 18, 2015
Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group ProtocolsCarrie B Moore, Anurag Verma, Sarah Pendergrass, et al.
Pageof 19